Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2023 18:05 ET | Source: Rain Oncology Inc.

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”)...
November 09, 2023 16:01 ET | Source: Rain Oncology Inc.

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on...
October 16, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra...
August 10, 2023 16:05 ET | Source: Rain Oncology Inc.

Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations...
July 26, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and...
May 30, 2023 08:30 ET | Source: Rain Oncology Inc.

Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs

– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the...
November 23, 2022 08:00 ET | Source: Rain Therapeutics Inc

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
November 18, 2022 08:00 ET | Source: Rain Therapeutics Inc

Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference

NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
November 17, 2022 13:05 ET | Source: Rain Therapeutics Inc

Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

NEWARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
November 14, 2022 08:00 ET | Source: Rain Therapeutics Inc

Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product...